As can be observed, all NAFLD groups except the combination therapy group (NAFLD+LGG+Exe) showed a significant decrease in α-SMA compared to the healthy control group (p < 0.05). The gene discussed is ACTA1; the disease is metabolic dysfunction-associated steatotic liver disease.